Q-omics provides the consensus-scored RPL5P16 profile across patient tissues and cancer cell-line models. RPL5P16 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL5P16 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, RPL5P16 RNA expression shows 9,489 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, and LUAD as cancer lineages where RPL5P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P16 survival associations across molecular data types. RPL5P16 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P16 RNA expression–survival associations across cancer types. High RPL5P16 expression shows unfavorable associations in HNSC, KIRC, THCA, GBM and MESO, but favorable associations in ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL5P16 RNA expression.
This table summarizes RPL5P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P16 shows higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher RPL5P16 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .033).
This table shows molecular features associated with RPL5P16 in patient tissues and cancer cell lines. In patient samples, RPL5P16 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
